Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

Robert Hoffman

Robert Hoffman

  • More than 20 years’ experience in leading and managing global biotechnology companies, and working with a number of public, late-stage oncology companies
  • Currently, Board member & Audit Committee Chair – Kura Oncology (Nasdaq KURA) and Antibe Therapeutics (TSX ATE); Board member, Chairman of the Board – Kintara Therapeutics (Nasdaq KTRA)
  • Previously, served as Chief Financial Officer and Senior Vice President, Finance of Nasdaq-listed Heron Therapeutics (Nasdaq HRTX).
  • Other experiences include Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals and Chief Financial Officer of AnaptysBio
  • Part of the founding management team of Arena Pharmaceuticals in 1997 until 2015
  • BBA from St. Bonaventure University
  • Chair of the Audit Committee
  • Member of the Remuneration Committee

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Careers

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Tel: +65 6222 4235
Fax: +65 6225 2419

contact@aslanpharma.com